Kymera Therapeutics, Inc. Q4 FY2025 earnings call

Nello Meinolfi started by recapping 2025 as a breakout year. Progress in the STAT6 degrader program was highlighted, including results from Phase 1 Healthy Volunteer Study and Phase 1b study in AD. Pipeline advancement with RFI program and collaborations with Sanofi and Gilead. Bruce Jacobs discussed fourth quarter results, with collaboration revenue from Gilead, R&D and G&A expenses, and cash balance. Jared Golub discussed KT621 Phase 2B trials in AD and asthma, and KT579's Phase 1 Healthy Volunteer Trial and clinical development strategy.

For KT621, expect to complete enrollment in AD study in 2026 and share data by mid-2027; first patient dosed in asthma trial last month, data expected in late 2027. KT579 expects to complete Phase 1 Healthy Volunteer Study and share data later in 2026, then advance to patient proof of concept study for lupus. Sanofi expected to start healthy volunteer phase one trial with KT485 in 2026. Goal to announce at least one new program annually, targeting second half of 2026 to share new development candidate program.

Q: About AD treatment vision and IRF-5 healthy volunteer trial; A: Nello discussed AD market potential and non-zero-sum game of therapies, Jared explained IRF-5 healthy volunteer trial's translational info.

Q: On K261 phase 2Bs and IRF-5 program priorities; A: Jeff was told phase 2Bs will have end-of-study data, IRF-5 program priorities guided by genetics and preclinical data.

Q: Gating factors for starting K261 phase threes; A: Need to complete phase 2, have FDA meeting post-phase 2, and expect to start phase 3s as much in parallel as possible.

Q: Efficacy improvements of K621 over dupilumab and respiratory preclinical data; A: Nello said preclinical data shows K621 at least as good, clinical data shows robust activity.

Q: Compliance and durability of K621; A: Nello mentioned measures for adherence and protein degrader's protection against missed doses.

Q: IRF5 targeting risk and safety; A: Nello and Jared explained IRF5's selectivity and safe degradation due to restricted expression.

Q: 579 healthy volunteer study model and biomarker reduction; A: Nello discussed model preference, Joe explained biomarkers.

Q: IRF5 degradation in tissues; A: Brian was told IRF5 expression in healthy volunteer skin is extremely low.

Q: K621's opportunity in asthma; A: Nello said STAT6 biology supports K621's potential in asthma.

Q: Evolving competitive landscape in AD and IRF5; A: Nello discussed competitive landscape and IRF5's target.

Q: Enrollment in K261 phase 2B and mitigation of placebo response; A: Nello said enrollment ongoing, measures taken for placebo response.

Q: Asthma trial dose levels, FENO enrichment, and competitive dynamics; A: Nello confirmed dose levels same as AD, FENO enrichment criteria, and enthusiasm for studies